Difference between revisions of "Vismodegib (Erivedge)"
m |
|||
| Line 16: | Line 16: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Hedgehog pathway inhibitors]] | ||
| + | [[Category:SMO inhibitors]] | ||
| + | |||
| + | [[Category:Basal cell and squamous cell skin cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 14:17, 7 October 2014
Also known as GDC-0449. FDA approved 1/30/2012.
General information
Class/mechanism: Hedgehog pathway inhibitor. Vismodegib binds to and inhibits the transmembrane protein Smoothened (SMO), which is part of the Hedgehog signal transduction pathway that is clinically relevant in diseases such as basal cell cancer.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]